Exposure-based CBT for Itching in Atopic Dermatitis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 9
- 试验地点
- 2
- 主要终点
- Severity Scoring of Atopic Dermatitis index (SCORAD)
研究概览
简要总结
Atopic dermatitis is an inflammatory skin disease characterized by itching, dry skin and recurrent inflammatory eczema. It is one of the most common skin diseases and is associated with reduced quality of life, functional impairment and sleep difficulties. The present study aims to investigate a new exposure-based cognitive behavioral psychological treatment for the disorder. The trial is a small scale open trial (n=25) with assessments at baseline, post-treatment and 6-month follow-up. The primary outcome is the SCORAD.
详细描述
Atopic dermatitis (AD)is an inflammatory skin disease characterized by itching, dry skin and recurrent inflammatory eczema. It is one of the most common skin diseases and is associated with reduced quality of life, functional impairment and sleep difficulties. There are currently no pharmacological treatments that are effective in curing the disorder in the longer-term. Itching is one of the core symptoms in AD and it has been shown that the behavioral response to itching, scratching, has a maintaining function in AD. Reducing scratching may therefore play an important role in alleviating AD. Although behavioral aspects play a significant role in AD only a few studies have investigated the effect of psychological treatment for AD. These studies have shown promising results and the present study aim to add to the body of knowledge by testing a new form of cognitive behavioral treatment for AD. This new treatment is based on the idea that patients could benefit from training in exposure to events that could lead to increase in itching while refraining from scratching. To enable this the treatment incorporates more recently developed cognitive behavioral components such as mindfulness training.
The present study aims to investigate a new exposure-based cognitive behavioral psychological treatment for the disorder. The trial is a small scale open trial (n=25) with assessments at baseline, post-treatment and 6-month follow-up. The primary outcome is the SCORAD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of AD with at least moderate severity
- •AD for at least 6 months
- •Age 18-65
- •Ability to read and write in Swedish
排除标准
- •Serious psychiatric illness
- •Concurrent light treatment or peroral treatment for AD
- •Pregnancy
- •Other concurrent or recently finished psychological treatment for AD
结局指标
主要结局
Severity Scoring of Atopic Dermatitis index (SCORAD)
时间窗: Change from baseline to 10 weeks follow-up and 6-month follow-up
次要结局
- Trimbos and Institute of Technology Cost Questionnaire for Psychiatric illness (TIC-P)(Change from baseline to 10 weeks follow-up and 6-month follow-up)
- Beck Anxiety Inventory(Change from baseline to 10 weeks follow-up and 6-month follow-up)
- Alcohol Disorders Identification Test(Baseline only)
- Montgomery-Åsberg Depression Rating Scale-Self-rated(Change from baseline to 10 weeks follow-up and 6-month follow-up)
- Quality of Life Inventory(Change from baseline to 10 weeks follow-up and 6-month follow-up)
- SRH-5(Change from baseline to 10 weeks follow-up and 6-month follow-up)
研究者
Erik Hedman
Phd, psychologist
Karolinska Institutet